Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
AFT Leaves X Over AI-Generated Images of Minors 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
Dublin, April 04, 2017 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Personalized Medicine - Scientific and Commercial Aspects" to their offering.
Several players are involved in the development of personalized therapy. Pharmaceutical and biotechnology companies have taken a leading role in this venture in keeping with their future role as healthcare enterprises rather than mere developers of technologies and manufacturers of medicines.
Ethical issues are involved in the development of personalized medicine mainly in the area of genetic testing. These along with social issues and consideration of race in the development of personalized medicine are discussed. Regulatory issues are discussed mainly with reference to the FDA guidelines on pharmacogenomics.
Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2016-2026.
Profiles of 320 companies involved in developing technologies for personalized medicines, along with 584 collaborations are included in the part II of the report. Finally the bibliography contains over 750 selected publications cited in the report.The report is supplemented by 80 tables and 38 figures.
Key Topics Covered:
Part I: Scientific & Commercial Aspects
Executive Summary
1. Basic Aspects
2. Molecular Diagnostics in Personalized Medicine
3. Pharmacogenetics
4. Pharmacogenomics
5. Role of Pharmacoproteomics
6. Role of Metabolomics in Personalized Medicine
7. Personalized Biological Therapies
8. Personalized Non-pharmacological Therapies
9. Personalized Medicine in Major Therapeutic Areas
10. Personalized Therapy of Cancer
11. Development of Personalized Medicine
12. Ethical, Legal and Regulatory Aspects of Personalized Medicine.
13. Commercial Aspects of Personalized Medicine
14. References
Part II: Companies
14. Companies Involved in Developing Personalized Medicine
For more information about this report visit http://www.researchandmarkets.com/research/t869km/personalized
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Genomics
